{"hands_on_practices": [{"introduction": "The first step in quantitative PET analysis often involves the Standardized Uptake Value (SUV), a straightforward metric that normalizes tissue radioactivity by injected dose and body weight. While widely used in clinical settings for its simplicity, a deep understanding of the SUV requires knowing not only how to calculate it but also what it physiologically represents. This practice [@problem_id:4600473] will guide you through calculating an SUV from typical clinical data and, more importantly, interpreting its value and recognizing its fundamental limitations as a composite signal.", "problem": "A clinical trial uses Positron Emission Tomography (PET) to quantify tissue uptake of a radiolabeled drug at a single time point. At $60$ minutes post-injection, the scanner reports a decay-corrected tissue radioactivity concentration of $5.0$ $\\mathrm{kBq}\\,\\mathrm{mL}^{-1}$ in a target organ. The injected activity is $370$ $\\mathrm{MBq}$ of an ${}^{18}\\text{F}$-labeled ligand, and the subject’s body weight is $70$ $\\mathrm{kg}$. Starting from the standard definition that the standardized uptake value (SUV) is the ratio of tissue radioactivity concentration to the injected activity normalized by body mass, and adopting the conventional approximation that tissue density is $1$ $\\mathrm{g}\\,\\mathrm{mL}^{-1}$, compute the SUV for the target organ at $60$ minutes post-injection. Round your answer to three significant figures. Express the SUV as a unitless ratio. Then, interpret the physiological meaning of this SUV in the context of clinical pharmacology, explicitly stating what this ratio compares and one key limitation of interpreting SUV for a receptor-binding radiotracer.", "solution": "The problem statement has been critically validated and found to be scientifically grounded, well-posed, objective, and self-contained. All provided data and definitions are standard within the field of nuclear medicine and clinical pharmacology, and the requested tasks are formally solvable. Therefore, I will proceed with the solution.\n\nThe problem requires the calculation of the Standardized Uptake Value (SUV), followed by an interpretation of its meaning and a discussion of its limitations.\n\n**1. Calculation of the Standardized Uptake Value (SUV)**\n\nThe Standardized Uptake Value (SUV) is defined as the ratio of the radioactivity concentration in a region of interest (tissue) to the average radioactivity concentration in the body, assuming uniform distribution of the injected dose. The formal definition is:\n$$\n\\text{SUV} = \\frac{\\text{Tissue Activity Concentration } [\\text{Activity/Mass}]}{\\text{Injected Dose } [\\text{Activity}] / \\text{Body Mass } [\\text{Mass}]}\n$$\nLet $C_{\\text{tissue,mass}}$ be the tissue activity concentration per unit mass, $A_{\\text{inj}}$ be the injected activity, and $W$ be the subject's body weight. The formula is:\n$$\n\\text{SUV} = \\frac{C_{\\text{tissue,mass}}}{A_{\\text{inj}} / W}\n$$\nThe problem provides the following givens:\n- Decay-corrected tissue radioactivity concentration, $C_{\\text{tissue,vol}} = 5.0 \\, \\mathrm{kBq}\\,\\mathrm{mL}^{-1}$\n- Injected activity, $A_{\\text{inj}} = 370 \\, \\mathrm{MBq}$\n- Subject's body weight, $W = 70 \\, \\mathrm{kg}$\n- Assumed tissue density, $\\rho_{\\text{tissue}} = 1 \\, \\mathrm{g}\\,\\mathrm{mL}^{-1}$\n\nTo ensure the SUV is a dimensionless quantity, all units must be consistent. We are given the tissue concentration in units of activity per volume ($\\mathrm{kBq}\\,\\mathrm{mL}^{-1}$). We must convert this to activity per mass using the provided tissue density.\n$$\nC_{\\text{tissue,mass}} = \\frac{C_{\\text{tissue,vol}}}{\\rho_{\\text{tissue}}} = \\frac{5.0 \\, \\mathrm{kBq}\\,\\mathrm{mL}^{-1}}{1 \\, \\mathrm{g}\\,\\mathrm{mL}^{-1}} = 5.0 \\, \\mathrm{kBq}\\,\\mathrm{g}^{-1}\n$$\nNow, we must express all quantities in a consistent set of units, for example, Bq and g.\n$$\nC_{\\text{tissue,mass}} = 5.0 \\, \\mathrm{kBq}\\,\\mathrm{g}^{-1} = 5.0 \\times 10^3 \\, \\mathrm{Bq}\\,\\mathrm{g}^{-1}\n$$\n$$\nA_{\\text{inj}} = 370 \\, \\mathrm{MBq} = 370 \\times 10^6 \\, \\mathrm{Bq}\n$$\n$$\nW = 70 \\, \\mathrm{kg} = 70 \\times 10^3 \\, \\mathrm{g}\n$$\nFirst, calculate the denominator, which represents the average concentration in the body:\n$$\n\\frac{A_{\\text{inj}}}{W} = \\frac{370 \\times 10^6 \\, \\mathrm{Bq}}{70 \\times 10^3 \\, \\mathrm{g}} = \\frac{370}{70} \\times 10^{3} \\, \\mathrm{Bq}\\,\\mathrm{g}^{-1} = \\frac{37}{7} \\times 10^3 \\, \\mathrm{Bq}\\,\\mathrm{g}^{-1}\n$$\nNow, compute the SUV:\n$$\n\\text{SUV} = \\frac{C_{\\text{tissue,mass}}}{A_{\\text{inj}} / W} = \\frac{5.0 \\times 10^3 \\, \\mathrm{Bq}\\,\\mathrm{g}^{-1}}{\\frac{37}{7} \\times 10^3 \\, \\mathrm{Bq}\\,\\mathrm{g}^{-1}} = \\frac{5.0}{\\frac{37}{7}} = \\frac{5.0 \\times 7}{37} = \\frac{35}{37}\n$$\nThe numerical value is:\n$$\n\\text{SUV} = \\frac{35}{37} \\approx 0.9459459...\n$$\nRounding to three significant figures as requested, we get:\n$$\n\\text{SUV} \\approx 0.946\n$$\nThe result is a unitless ratio, as expected. The explicit mention of \"decay-corrected tissue radioactivity\" confirms the standard practice for SUV calculation, where the tissue radioactivity is corrected for physical decay back to the time of injection, while the injected dose is the activity administered at the time of injection.\n\n**2. Physiological Interpretation of the SUV**\n\nThe SUV is a semiquantitative index of radiotracer uptake. It compares the measured concentration of the radiolabeled drug in the target organ to a reference concentration. This reference concentration is a theoretical value representing the concentration that would exist if the entire injected dose were distributed uniformly throughout the subject's total body mass.\n\n- An SUV equal to $1$ implies that the tracer concentration in the tissue is exactly the same as the body average.\n- An SUV greater than $1$ signifies that the tissue concentrates the tracer above the body average, suggesting phenomena such as high blood flow, high metabolic activity, or specific binding to molecular targets.\n- An SUV less than $1$ indicates that the tracer concentration is below the body average.\n\nIn this case, the calculated SUV is $0.946$. This value is slightly less than $1$. Physiologically, this means that at $60$ minutes post-injection, the concentration of the radiolabeled drug in the target organ is approximately $94.6\\%$ of the hypothetical uniform body concentration. This suggests that the target organ does not exhibit significant specific accumulation or trapping of this particular drug relative to the rest of the body at this time point. This observation could be due to various factors, including low blood perfusion to the organ, low density of the target receptors for the drug, or rapid clearance of the drug from the organ.\n\n**3. Key Limitation of SUV for a Receptor-Binding Radiotracer**\n\nA principal limitation of using SUV to interpret the signal from a receptor-binding radiotracer is that it is a composite measure that fails to distinguish between specific binding and other contributing factors. The total radioactivity signal measured by the PET scanner in a tissue region, and thus the calculated SUV, is a summation of radioactivity from three distinct compartments:\n1.  Radiotracer still in the blood plasma within the tissue's vasculature (the blood pool).\n2.  Radiotracer that has entered the tissue but is either freely diffusing or bound non-specifically to other macromolecules.\n3.  Radiotracer that is specifically bound to the target receptors of interest.\n\nThe SUV provides a single value that amalgamates all these contributions. A high SUV does not unequivocally prove high specific receptor binding. It could equally be caused by high blood flow (delivering more tracer to the region), high non-specific binding, or slow clearance of the unbound tracer from the tissue. To isolate the signal corresponding to specific receptor binding, which is often the quantity of pharmacological interest (e.g., to determine receptor occupancy by a therapeutic drug), more sophisticated analysis methods are required. These methods, known as kinetic modeling, use dynamic PET data (a series of images over time) to mathematically separate the contributions from the different compartments, thereby providing a more accurate and specific measure of receptor availability, such as the binding potential ($BP_{ND}$).", "answer": "$$\\boxed{0.946}$$", "id": "4600473"}, {"introduction": "A core tenet of using PET as a measurement tool in pharmacology is the \"tracer principle,\" which dictates that the radiolabeled molecule should act as a passive probe without perturbing the biological system it aims to measure. This principle is operationalized through microdosing, where the injected mass of the compound is kept low enough to avoid significant target occupancy and any resulting pharmacological effects. This exercise [@problem_id:4600416] provides a hands-on calculation to determine the maximum allowable injected mass to satisfy a specific occupancy constraint, connecting the abstract tracer principle to concrete pharmacological parameters like the dissociation constant ($K_{D}$) and biophase distribution.", "problem": "A positron emission tomography (PET) radiotracer with equilibrium dissociation constant $K_{D}$ is administered intravenously as a bolus to a human subject. The tracer is assumed to rapidly and uniformly distribute into an effective biophase volume of $10$ L over the time window relevant for assessing target engagement, with negligible metabolism or elimination during that window. The plasma free fraction $f_{P}$ denotes the fraction of the tracer in plasma that is not bound to plasma proteins and is free to diffuse to the biophase and interact with the target. Assume that the free tracer concentration in the biophase equals the product of $f_{P}$ and the total tracer concentration in the biophase.\n\nUsing the mass action framework for reversible ligand–receptor binding at equilibrium and the definition of $K_{D}$, determine the maximum allowable injected mass (in nmol) that ensures the fractional target occupancy remains strictly below $0.05$ throughout the initial distribution equilibrium, given $K_{D}=1$ nM, $f_{P}=0.5$, and a biophase distribution volume of $10$ L. Round your final numerical answer to four significant figures and express it in nmol.\n\nIn your reasoning, explicitly connect the occupancy constraint to the allowable free tracer concentration and then to the injected mass via the stated biophase assumptions. Briefly explain, without changing the required calculation, the trade-off between maintaining low injected mass to avoid pharmacological perturbation and achieving sufficient PET counting statistics, highlighting the role of specific activity in reconciling these constraints.", "solution": "The problem statement is validated according to the specified criteria.\n\n### Problem Validation\n\n**Step 1: Extract Givens**\n- Equilibrium dissociation constant: $K_{D} = 1$ nM\n- Effective biophase distribution volume: $V_{biophase} = 10$ L\n- Plasma free fraction: $f_{P} = 0.5$\n- Assumption 1: Rapid and uniform distribution into the biophase volume.\n- Assumption 2: Negligible metabolism or elimination during the relevant time window.\n- Assumption 3: The free tracer concentration in the biophase, $[L]_{free,biophase}$, is related to the total tracer concentration in the biophase, $[L]_{total,biophase}$, by the equation: $[L]_{free,biophase} = f_{P} \\times [L]_{total,biophase}$.\n- Constraint: Fractional target occupancy, $O$, must be strictly below $0.05$.\n- Objective: Determine the maximum allowable injected mass, $M_{injected}$, in nanomoles (nmol).\n- Requirement: Round the final answer to four significant figures.\n- Ancillary task: Briefly explain the trade-off between low injected mass and PET signal, and the role of specific activity.\n\n**Step 2: Validate Using Extracted Givens**\n- **Scientific Grounding (Critical)**: The problem is firmly based on the law of mass action, a cornerstone of pharmacology and biochemistry, and uses standard pharmacokinetic and pharmacodynamic concepts ($K_D$, $f_{P}$, occupancy, distribution volume). The premises are scientifically sound.\n- **Well-Posed**: The problem provides all necessary data and defines the relationships between them, leading to a unique, solvable mathematical question.\n- **Objective (Critical)**: The problem is stated in precise, quantitative, and unbiased language.\n- **Completeness and Consistency**: The problem is self-contained. The provided assumptions, including the specific relationship between free and total concentrations in the biophase, create a complete and consistent framework for a solution.\n- **Realism**: The given values ($K_D=1$ nM, $f_P=0.5$, $V_{biophase}=10$ L) and constraints (occupancy $0.05$) are realistic for a microdosing PET study.\n- **Other Flaws**: The problem is not trivial, circular, ambiguous, or unverifiable.\n\n**Step 3: Verdict and Action**\nThe problem is **valid**. A reasoned solution will be provided.\n\n### Solution Derivation\n\nThe fractional target occupancy, $O$, at equilibrium is described by the law of mass action for a single-site ligand-receptor binding model. It relates the concentration of the free ligand (tracer), $[L]_{free}$, to the equilibrium dissociation constant, $K_{D}$.\n$$\nO = \\frac{\\text{Concentration of occupied receptors}}{\\text{Total concentration of receptors}} = \\frac{[L]_{free}}{[L]_{free} + K_{D}}\n$$\nThe problem imposes the strict constraint that the occupancy must remain below $0.05$.\n$$\nO  0.05\n$$\nSubstituting the expression for occupancy, we get an inequality for the maximum allowable free tracer concentration in the biophase, $[L]_{free,biophase}$.\n$$\n\\frac{[L]_{free,biophase}}{[L]_{free,biophase} + K_{D}}  0.05\n$$\nTo find the maximum allowable concentration, we solve this inequality for $[L]_{free,biophase}$:\n$$\n[L]_{free,biophase}  0.05 \\times ([L]_{free,biophase} + K_{D})\n$$\n$$\n[L]_{free,biophase}  0.05 [L]_{free,biophase} + 0.05 K_{D}\n$$\n$$\n[L]_{free,biophase} - 0.05 [L]_{free,biophase}  0.05 K_{D}\n$$\n$$\n0.95 [L]_{free,biophase}  0.05 K_{D}\n$$\n$$\n[L]_{free,biophase}  \\frac{0.05}{0.95} K_{D} = \\frac{1}{19} K_{D}\n$$\nThis result establishes the upper limit for the free tracer concentration at the target site.\n\nNext, we must connect this concentration to the total injected mass of the tracer, $M_{injected}$. The problem states that the tracer distributes uniformly into an effective biophase volume, $V_{biophase} = 10$ L. The total tracer concentration in this volume, $[L]_{total,biophase}$, is therefore the total molar amount, $M_{injected}$, divided by the volume.\n$$\n[L]_{total,biophase} = \\frac{M_{injected}}{V_{biophase}}\n$$\nA crucial assumption provided is the relationship between the free and total tracer concentrations in the biophase, which involves the plasma free fraction, $f_{P}$.\n$$\n[L]_{free,biophase} = f_{P} \\times [L]_{total,biophase}\n$$\nSubstituting the expression for $[L]_{total,biophase}$:\n$$\n[L]_{free,biophase} = f_{P} \\times \\frac{M_{injected}}{V_{biophase}}\n$$\nNow, we combine the occupancy constraint with this expression for the free concentration. To keep occupancy below $0.05$, the free concentration must be less than $\\frac{1}{19} K_{D}$.\n$$\nf_{P} \\frac{M_{injected}}{V_{biophase}}  \\frac{1}{19} K_{D}\n$$\nWe can now solve for the maximum allowable injected mass, $M_{injected, max}$.\n$$\nM_{injected}  \\frac{K_{D} V_{biophase}}{19 f_{P}}\n$$\nThe maximum allowable mass is thus:\n$$\nM_{injected, max} = \\frac{K_{D} V_{biophase}}{19 f_{P}}\n$$\nWe substitute the given values, ensuring consistent units.\n- $K_{D} = 1$ nM $= 1 \\times 10^{-9}$ mol/L\n- $V_{biophase} = 10$ L\n- $f_{P} = 0.5$\n\n$$\nM_{injected, max} = \\frac{(1 \\times 10^{-9} \\, \\text{mol/L}) \\times (10 \\, \\text{L})}{19 \\times 0.5} = \\frac{10 \\times 10^{-9} \\, \\text{mol}}{9.5}\n$$\n$$\nM_{injected, max} = \\frac{10}{9.5} \\times 10^{-9} \\, \\text{mol} \\approx 1.0526315... \\times 10^{-9} \\, \\text{mol}\n$$\nThe problem requires the answer in nanomoles (nmol), where $1$ nmol $= 10^{-9}$ mol.\n$$\nM_{injected, max} \\approx 1.0526315... \\, \\text{nmol}\n$$\nRounding to four significant figures gives:\n$$\nM_{injected, max} = 1.053 \\, \\text{nmol}\n$$\n\nRegarding the trade-off, there is a fundamental conflict in PET tracer studies between pharmacological validity and imaging feasibility. On one hand, the injected mass of the tracer must be kept extremely low (a \"microdose\") to ensure that it acts as a passive probe without perturbing the biological system it is meant to measure. As calculated, this requires limiting the total injected mass to avoid significant target occupancy and potential pharmacological effects. On the other hand, PET imaging requires a sufficient quantity of radioactivity to be injected to generate a clear signal with an acceptable signal-to-noise ratio for reliable quantification. Too little radioactivity results in noisy, unusable images.\n\nThe role of specific activity is to resolve this conflict. Specific activity is defined as the ratio of radioactivity to mass (e.g., Bq/mol or Ci/mmol). A radiotracer with a very high specific activity packs a large amount of radioactivity into a very small mass. By synthesizing and using such high-specific-activity tracers, it becomes possible to inject a quantity of radioactivity sufficient for high-quality imaging while keeping the total chemical mass well below the threshold for pharmacological perturbation (i.e., maintaining low target occupancy). In essence, high specific activity decouples the imaging requirement (radioactive dose) from the pharmacological constraint (mass dose).", "answer": "$$\n\\boxed{1.053}\n$$", "id": "4600416"}, {"introduction": "The previous practice highlighted the need to limit the injected mass of a radiotracer to preserve the integrity of the biological system. However, PET imaging simultaneously requires a sufficient amount of radioactivity to generate a high-quality image with a strong signal-to-noise ratio. This exercise [@problem_id:4600461] tackles this apparent paradox by focusing on molar activity, the key radiochemical property that decouples the injected mass from the injected radioactivity. By working through the effects of altering molar activity, you will quantify how it directly impacts receptor occupancy and the apparent binding parameters, revealing its central role in enabling true microdosing studies.", "problem": "A Positron Emission Tomography (PET) radioligand is administered as a bolus with injected activity $A_0$ at the time of imaging. The radioligand’s molar activity (also called specific activity) at the time of injection is $A_m$, defined as radioactivity per amount of substance. The total injected molar amount is therefore $n = A_0/A_m$. For a narrow dosing range in a microdosing regime, assume the free ligand concentration at the receptor microdomain during the quantification window is proportional to the injected molar amount, $C_f = \\gamma n$, where $\\gamma$ is an empirically determined proportionality constant. Consider a receptor system at equilibrium with negligible endogenous competitor, governed by the law of mass action for a reversible $1:1$ ligand-receptor interaction with dissociation constant $K_D$. The fractional receptor occupancy by exogenous ligand (irrespective of isotopic label) is $f_{\\text{occ}} = \\frac{C_f}{K_D + C_f}$. The Binding Potential relative to nondisplaceable uptake (BP$_{\\text{ND}}$) is defined in the tracer limit by $BP_{\\text{ND}} = f_{\\text{ND}} \\frac{B_{\\text{avail}}}{K_D}$, where $f_{\\text{ND}}$ is the free fraction in the nondisplaceable compartment and $B_{\\text{avail}}$ is the density of available receptors; however, if $C_f$ is not negligible, naïvely interpreting equilibrium binding as if in the tracer limit biases the apparent $BP_{\\text{ND}}$.\n\nA radioligand is administered with $A_0 = 370$ MBq and initial molar activity $A_m^{(1)} = 74$ MBq/nmol. The dissociation constant is $K_D = 2.0$ nM. A prior calibration experiment establishes $\\gamma = 0.020$ nM per nmol over this dosing range. All other physiological and kinetic factors remain unchanged between conditions.\n\nFrom first principles of equilibrium receptor binding and the definition of molar activity, derive and compute how a twofold increase in molar activity to $A_m^{(2)} = 2 A_m^{(1)}$ alters (i) the cold-mass receptor occupancy and (ii) the apparent $BP_{\\text{ND}}$ one would estimate if finite $C_f$ is not accounted for.\n\nReport your final results as a two-entry row vector $\\begin{pmatrix} r_{\\text{occ}}  r_{\\text{BP}} \\end{pmatrix}$, where $r_{\\text{occ}}$ is the ratio of fractional occupancy after doubling $A_m$ to that at baseline, and $r_{\\text{BP}}$ is the ratio of the apparent $BP_{\\text{ND}}$ after doubling $A_m$ to that at baseline. Round your two numerical answers to four significant figures. The final answer is dimensionless and requires no units.", "solution": "### Step 1: Extract Givens\nThe problem provides the following data, variables, and definitions:\n-   Injected activity at time of imaging: $A_0 = 370$ MBq\n-   Initial molar activity (baseline): $A_m^{(1)} = 74$ MBq/nmol\n-   Condition for the second state: $A_m^{(2)} = 2 A_m^{(1)}$\n-   Dissociation constant: $K_D = 2.0$ nM\n-   Proportionality constant relating injected molar amount to free ligand concentration: $\\gamma = 0.020$ nM per nmol\n-   Definition of total injected molar amount: $n = A_0/A_m$\n-   Definition of free ligand concentration at the receptor: $C_f = \\gamma n$\n-   Definition of fractional receptor occupancy: $f_{\\text{occ}} = \\frac{C_f}{K_D + C_f}$\n-   Definition of Binding Potential in the tracer limit: $BP_{\\text{ND}} = f_{\\text{ND}} \\frac{B_{\\text{avail}}}{K_D}$\n-   The problem requires deriving and computing two ratios:\n    1.  $r_{\\text{occ}}$: the ratio of fractional occupancy after doubling $A_m$ to that at baseline.\n    2.  $r_{\\text{BP}}$: the ratio of the apparent $BP_{\\text{ND}}$ after doubling $A_m$ to that at baseline.\n-   The final results should be reported as a row vector $\\begin{pmatrix} r_{\\text{occ}}  r_{\\text{BP}} \\end{pmatrix}$, with values rounded to four significant figures.\n\n### Step 2: Validate Using Extracted Givens\nThe problem is scientifically grounded in the principles of receptor pharmacology and PET imaging. The concepts of molar activity, receptor-ligand equilibrium, the law of mass action, dissociation constant ($K_D$), fractional occupancy ($f_{\\text{occ}}$), and binding potential ($BP_{\\text{ND}}$) are standard in the field. The provided equations are correct representations of these principles. The numerical values are realistic for a human PET study using a radioligand with moderate affinity. The problem is well-posed, providing all necessary information to calculate the requested quantities. The language is objective and technical. The core of the problem, analyzing the effect of \"cold\" mass (non-radioactive ligand) on occupancy and apparent binding potential, is a fundamental and practical issue in quantitative PET imaging.\n\n### Step 3: Verdict and Action\nThe problem is valid. A complete solution will be provided.\n\n### Solution Derivation\nThe problem requires an analysis of two conditions: a baseline condition (denoted by superscript $(1)$) and a condition where the molar activity is doubled (denoted by superscript $(2)$). The injected activity, $A_0$, is constant between the two conditions.\n\nFirst, we determine the injected molar amount, $n$, and the resulting free ligand concentration, $C_f$, for each condition.\n\nFor the baseline condition (1):\nThe molar activity is $A_m^{(1)} = 74$ MBq/nmol.\nThe injected molar amount is:\n$$n^{(1)} = \\frac{A_0}{A_m^{(1)}} = \\frac{370 \\text{ MBq}}{74 \\text{ MBq/nmol}} = 5.0 \\text{ nmol}$$\nThe free ligand concentration at the receptor is:\n$$C_f^{(1)} = \\gamma n^{(1)} = (0.020 \\text{ nM/nmol}) \\times (5.0 \\text{ nmol}) = 0.10 \\text{ nM}$$\n\nFor the second condition (2):\nThe molar activity is doubled: $A_m^{(2)} = 2 A_m^{(1)} = 2 \\times 74 \\text{ MBq/nmol} = 148$ MBq/nmol.\nThe injected molar amount is:\n$$n^{(2)} = \\frac{A_0}{A_m^{(2)}} = \\frac{A_0}{2 A_m^{(1)}} = \\frac{1}{2} n^{(1)} = \\frac{1}{2} \\times 5.0 \\text{ nmol} = 2.5 \\text{ nmol}$$\nThe free ligand concentration at the receptor is:\n$$C_f^{(2)} = \\gamma n^{(2)} = \\gamma \\left(\\frac{1}{2} n^{(1)}\\right) = \\frac{1}{2} C_f^{(1)} = \\frac{1}{2} \\times 0.10 \\text{ nM} = 0.050 \\text{ nM}$$\n\nWith the free ligand concentrations established for both conditions, we can now calculate the requested ratios.\n\n**i) Ratio of fractional occupancy, $r_{\\text{occ}}$**\n\nThe fractional receptor occupancy, $f_{\\text{occ}}$, is given by $f_{\\text{occ}} = \\frac{C_f}{K_D + C_f}$.\nFor condition (1): $f_{\\text{occ}}^{(1)} = \\frac{C_f^{(1)}}{K_D + C_f^{(1)}}$\nFor condition (2): $f_{\\text{occ}}^{(2)} = \\frac{C_f^{(2)}}{K_D + C_f^{(2)}}$\n\nThe ratio $r_{\\text{occ}}$ is defined as:\n$$r_{\\text{occ}} = \\frac{f_{\\text{occ}}^{(2)}}{f_{\\text{occ}}^{(1)}} = \\frac{\\frac{C_f^{(2)}}{K_D + C_f^{(2)}}}{\\frac{C_f^{(1)}}{K_D + C_f^{(1)}}}$$\nSubstituting $C_f^{(2)} = \\frac{1}{2} C_f^{(1)}$:\n$$r_{\\text{occ}} = \\frac{\\frac{\\frac{1}{2}C_f^{(1)}}{K_D + \\frac{1}{2}C_f^{(1)}}}{\\frac{C_f^{(1)}}{K_D + C_f^{(1)}}} = \\frac{\\frac{1}{2}C_f^{(1)}}{K_D + \\frac{1}{2}C_f^{(1)}} \\cdot \\frac{K_D + C_f^{(1)}}{C_f^{(1)}} = \\frac{1}{2} \\frac{K_D + C_f^{(1)}}{K_D + \\frac{1}{2}C_f^{(1)}}$$\nNow, we substitute the numerical values $K_D = 2.0$ nM and $C_f^{(1)} = 0.10$ nM:\n$$r_{\\text{occ}} = \\frac{1}{2} \\frac{2.0 \\text{ nM} + 0.10 \\text{ nM}}{2.0 \\text{ nM} + \\frac{1}{2}(0.10 \\text{ nM})} = \\frac{1}{2} \\frac{2.10}{2.0 + 0.05} = \\frac{1}{2} \\frac{2.10}{2.05} = \\frac{2.10}{4.10}$$\n$$r_{\\text{occ}} \\approx 0.51219512...$$\nRounding to four significant figures, we get $r_{\\text{occ}} = 0.5122$.\n\n**ii) Ratio of apparent Binding Potential, $r_{\\text{BP}}$**\n\nThe true binding potential, $BP_{\\text{ND}}$, is defined in the tracer limit ($C_f \\to 0$). When $C_f$ is non-negligible, the specific binding of the radioligand is reduced due to competition from the co-injected non-radioactive ('cold') ligand. The measured or \"apparent\" $BP_{\\text{ND}}$, which we will denote as $BP_{\\text{app}}$, is proportional to the ratio of the total specifically bound ligand concentration, $B_{spec}$, to the free ligand concentration, $C_f$.\nFrom the law of mass action, the specifically bound concentration is $B_{spec} = \\frac{B_{\\text{avail}} C_f}{K_D + C_f}$.\nThe apparent binding potential is thus proportional to this ratio:\n$$BP_{\\text{app}} \\propto \\frac{B_{spec}}{C_f} = \\frac{B_{\\text{avail}}}{K_D + C_f}$$\nLet the proportionality constant be $k'$, so $BP_{\\text{app}} = k' \\frac{B_{\\text{avail}}}{K_D + C_f}$. Since $B_{\\text{avail}}$ and $k'$ are constants, $BP_{\\text{app}}$ is inversely proportional to $(K_D + C_f)$.\n\nThe ratio $r_{\\text{BP}}$ is defined as:\n$$r_{\\text{BP}} = \\frac{BP_{\\text{app}}^{(2)}}{BP_{\\text{app}}^{(1)}} = \\frac{k' \\frac{B_{\\text{avail}}}{K_D + C_f^{(2)}}}{k' \\frac{B_{\\text{avail}}}{K_D + C_f^{(1)}}} = \\frac{K_D + C_f^{(1)}}{K_D + C_f^{(2)}}$$\nSubstituting $C_f^{(2)} = \\frac{1}{2} C_f^{(1)}$:\n$$r_{\\text{BP}} = \\frac{K_D + C_f^{(1)}}{K_D + \\frac{1}{2}C_f^{(1)}}$$\nUsing the numerical values $K_D = 2.0$ nM and $C_f^{(1)} = 0.10$ nM:\n$$r_{\\text{BP}} = \\frac{2.0 \\text{ nM} + 0.10 \\text{ nM}}{2.0 \\text{ nM} + \\frac{1}{2}(0.10 \\text{ nM})} = \\frac{2.10}{2.05}$$\n$$r_{\\text{BP}} \\approx 1.02439024...$$\nRounding to four significant figures, we get $r_{\\text{BP}} = 1.024$.\n\nBy doubling the molar activity (while keeping injected activity constant), the injected mass is halved. This reduces receptor occupancy by the cold ligand ($r_{\\text{occ}} \\approx 0.5$), thereby increasing the apparent binding potential ($r_{\\text{BP}}  1$) because more receptors are available for the radiolabeled tracer portion.\n\nThe final results are $r_{\\text{occ}} \\approx 0.5122$ and $r_{\\text{BP}} \\approx 1.024$.", "answer": "$$\n\\boxed{\n\\begin{pmatrix}\n0.5122  1.024\n\\end{pmatrix}\n}\n$$", "id": "4600461"}]}